Search company, investor...

Stage

Seed | Dead

Total Raised

$500K

Last Raised

$500K

About CytoSolv

CytoSolv develops a drug to help heal wounds. The company is developing the drug from the brain cells of pigs.

Headquarters Location

Providence, Rhode Island, 02029,

United States

Loading...

Loading...

CytoSolv Patents

CytoSolv has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/10/2015

Skeletal system, Traumatology, Acetylcholinesterase inhibitors, Physiology, Inflammations

Application

Application Date

9/10/2015

Grant Date

Title

Related Topics

Skeletal system, Traumatology, Acetylcholinesterase inhibitors, Physiology, Inflammations

Status

Application

CytoSolv Frequently Asked Questions (FAQ)

  • Where is CytoSolv's headquarters?

    CytoSolv's headquarters is located at Providence.

  • What is CytoSolv's latest funding round?

    CytoSolv's latest funding round is Seed.

  • How much did CytoSolv raise?

    CytoSolv raised a total of $500K.

  • Who are the investors of CytoSolv?

    Investors of CytoSolv include Slater Technology Fund.

  • Who are CytoSolv's competitors?

    Competitors of CytoSolv include EQRx, Cognate BioServices, Ra Pharmaceuticals, SynDevRx, The Medicines Company and 7 more.

Loading...

Compare CytoSolv to Competitors

A
Auxeris Therapeutics

Auxeris Therapeutics, Inc. is engaged in osteoporosis drug development

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company focused on providing business intelligence in the pharmaceutical and biologic drugs sector. The company's main services include offering insights on life cycle management, brand erosion, generic entry, biosimilars, patents, sales, litigation, and more, all related to pharmaceutical and biologic drugs. The company primarily serves the biopharmaceutical industry. It is based in Troy, New York.

N
NeuroGenomeX

NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

Konova Logo
Konova

Konova offers anti-obesity drug development

S
SynDevRx

SynDevRx develops drugs that target both cancer and the underlying metabolic hormone dysfunction that drives it, with a particular emphasis on treating patients who are overweight, diabetic, or pre-diabetic. SynDevRx primarily serves the healthcare sector, specifically the oncology and metabolic disease segments. It was founded in 2007 and is based in Cambridge, Massachusetts.

P
Paloma Pharmaceuticals

Paloma Pharmaceuticals, Inc. is a drug development company focusing on pathologies with a vascular component including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (pulmonary fibrosis) endometriosis, osteoporosis and skin diseases (psoriasis and atopic dermatitis). Paloma owns the intellectual property relating to a series of , small molecule drugs created through an integrated design platform incorporating , customized and industry standard computational tools that has therapeutic potential for the treatment of the foregoing diseases.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.